Elanco Animal Health (NYSE:ELAN) Announces FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its FY 2026 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 1.170-1.200 for the period, compared to the consensus estimate of 1.130. The company issued revenue guidance of $5.2 billion, compared to the consensus revenue estimate of $5.1 billion. Elanco Animal Health also updated its Q4 2026 guidance to 0.160-0.190 EPS.

Elanco Animal Health Stock Up 8.3%

ELAN stock opened at $25.65 on Friday. Elanco Animal Health has a one year low of $19.40 and a one year high of $27.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. The firm’s fifty day moving average is $23.13 and its 200 day moving average is $23.82. The firm has a market cap of $12.81 billion, a PE ratio of -85.48, a P/E/G ratio of 2.28 and a beta of 1.73.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Friday, November 6th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.07. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.21 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company’s revenue was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.19 earnings per share. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. On average, research analysts forecast that Elanco Animal Health will post 1.13 EPS for the current year.

Analysts Set New Price Targets

ELAN has been the subject of several recent analyst reports. Morgan Stanley cut their price target on Elanco Animal Health from $26.00 to $25.00 and set an “equal weight” rating for the company in a research note on Thursday, October 29th. KeyCorp reiterated an “overweight” rating on shares of Elanco Animal Health in a research report on Wednesday, September 30th. UBS Group raised their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. The Goldman Sachs Group assumed coverage on Elanco Animal Health in a research report on Friday, October 16th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, September 4th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $29.33.

Insider Buying and Selling

In related news, Director Lawrence Kurzius purchased 40,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The stock was purchased at an average price of $23.40 per share, with a total value of $936,000.00. Following the completion of the acquisition, the director owned 188,647 shares in the company, valued at $4,414,339.80. This trade represents a 26.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Shiv O’Neill acquired 3,998 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, August 18th. The shares were bought at an average price of $23.58 per share, for a total transaction of $94,272.84. Following the transaction, the insider owned 87,832 shares of the company’s stock, valued at $2,071,078.56. This represents a 4.77% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 48,998 shares of company stock valued at $1,139,373 over the last ninety days. 1.14% of the stock is currently owned by company insiders.

Trending Headlines about Elanco Animal Health

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Third-quarter adjusted EPS was $0.27, ahead of the $0.20 consensus, while revenue rose 11% year over year to $1.265 billion, topping estimates. Elanco also reported 9% organic constant-currency growth and gross-margin expansion. Read More.
• Positive Sentiment: Elanco raised its 2026 adjusted EPS outlook to $1.17–$1.20, versus the $1.13 consensus, and revenue guidance to $5.155–$5.18 billion, above the $5.1 billion consensus. It also lifted its innovation revenue target and improved its year-end net-leverage target to about 2.9x adjusted EBITDA. Read More.
• Positive Sentiment: Company survey findings offered further demand support: 93% of pet owners surveyed said they maintained or increased pet spending in the prior three months despite cost pressures. Read More.
• Neutral Sentiment: Fourth-quarter adjusted EPS guidance of $0.16–$0.19 brackets the $0.18 consensus, while revenue guidance of $1.2 billion matches estimates. Elanco’s early 2027 outlook calls for growth broadly in line with its previously stated long-term targets, rather than a further acceleration. Read More.

Elanco Animal Health Company Profile

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health.

For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

The company traces its origins to Eli Lilly’s animal health business, established in 1954, and became an independent public company in 2018.